Industry Comparison
Select Language
Current language: English (2023)
You are viewing information about the following Industries:
-
Medical Equipment & Supplies
The Medical Equipment & Supplies industry researches, develops and produces medical, surgical, dental, ophthalmic and veterinary instruments and devices. Hospitals, clinics and laboratories use these products, which range from disposable items to highly specialised equipment. The increased prevalence of diseases associated with unhealthy lifestyles and an ageing population are important factors that may encourage growth in this industry. Emerging markets and the expansion of health insurance may contribute to further growth. However, the extension of government insurance programmes, provider and payer consolidation, and regulatory emphasis on reduced costs in all markets may result in downward pricing pressure. -
Health Care Distributors
Health care distributors purchase, inventory and sell pharmaceutical products and medical equipment to hospitals, pharmacies and physicians. Demand for the industry’s services is driven largely by insurance rates, pharmaceutical spending, illness and demographics. The health care sector continues to face an emphasis on reduced costs and improved efficiencies, which also will affect the Health Care Distributors industry. Entities in this industry face challenges from consolidation and partnerships between pharmacies, payers and manufacturers.
Relevant Issues for both Industries (8 of 26)
Why are some issues greyed out?
The SASB Standards vary by industry based on the different sustainability-related risks and opportunities within an industry. The issues in grey were not identified during the standard-setting process as the most likely to be useful to investors, so they are not included in the Standard. Over time, as the ISSB continues to receive market feedback, some issues may be added or removed from the Standard. Each company determines which sustainability-related risks and opportunities are relevant to its business. The Standard is designed for the typical company in an industry, but individual companies may choose to report on different sustainability-related risks and opportunities based on their unique business model.-
Environment
-
GHG Emissions
The category addresses direct (Scope 1) greenhouse gas (GHG) emissions that a company generates through its operations. This includes GHG emissions from stationary (e.g., factories, power plants) and mobile sources (e.g., trucks, delivery vehicles, planes), whether a result of combustion of fuel or non-combusted direct releases during activities such as natural resource extraction, power generation, land use, or biogenic processes. The category further includes management of regulatory risks, environmental compliance, and reputational risks and opportunities, as they related to direct GHG emissions. The seven GHGs covered under the Kyoto Protocol are included within the category—carbon dioxide (CO2), methane (CH4), nitrous oxide (N2O), hydrofluorocarbons (HFCs), perfluorocarbons (PFCs), sulfur hexafluoride (SF6), and nitrogen trifluoride (NF3). - Air Quality
- Energy Management
- Water & Wastewater Management
- Waste & Hazardous Materials Management
- Ecological Impacts
-
-
Social Capital
- Human Rights & Community Relations
- Customer Privacy
- Data Security
-
Access & Affordability
The category addresses a company’s ability to ensure broad access to its products and services, specifically in the context of underserved markets and/or population groups. It includes the management of issues related to universal needs, such as the accessibility and affordability of health care, financial services, utilities, education, and telecommunications. -
Product Quality & Safety
The category addresses issues involving unintended characteristics of products sold or services provided that may create health or safety risks to end-users. It addresses a company’s ability to offer manufactured products and/or services that meet customer expectations with respect to their health and safety characteristics. It includes, but is not limited to, issues involving liability, management of recalls and market withdrawals, product testing, and chemicals/content/ingredient management in products. -
Customer Welfare
The category addresses customer welfare concerns over issues including, but not limited to, health and nutrition of foods and beverages, antibiotic use in animal production, and management of controlled substances. The category addresses the company’s ability to provide consumers with manufactured products and services that are aligned with societal expectations. It does not include issues directly related to quality and safety malfunctions of manufactured products and services, but instead addresses qualities inherent to the design and delivery of products and services where customer welfare may be in question. The scope of the category also captures companies’ ability to prevent counterfeit products. -
Selling Practices & Product Labeling
The category addresses social issues that may arise from a failure to manage the transparency, accuracy, and comprehensibility of marketing statements, advertising, and labeling of products and services. It includes, but is not limited to, advertising standards and regulations, ethical and responsible marketing practices, misleading or deceptive labeling, as well as discriminatory or predatory selling and lending practices. This may include deceptive or aggressive selling practices in which incentive structures for employees could encourage the sale of products or services that are not in the best interest of customers or clients.
-
Human Capital
- Labour Practices
- Employee Health & Safety
- Employee Engagement, Diversity & Inclusion
-
Business Model and Innovation
-
Product Design & Lifecycle Management
The category addresses incorporation of environmental, social, and governance (ESG) considerations in characteristics of products and services provided or sold by the company. It includes, but is not limited to, managing the lifecycle impacts of products and services, such as those related to packaging, distribution, use-phase resource intensity, and other environmental and social externalities that may occur during their use-phase or at the end of life. The category captures a company’s ability to address customer and societal demand for more sustainable products and services as well as to meet evolving environmental and social regulation. It does not address direct environmental or social impacts of the company’s operations nor does it address health and safety risks to consumers from product use, which are covered in other categories. - Business Model Resilience
-
Supply Chain Management
The category addresses management of environmental, social, and governance (ESG) risks within a company’s supply chain. It addresses issues associated with environmental and social externalities created by suppliers through their operational activities. Such issues include, but are not limited to, environmental responsibility, human rights, labour practices, and ethics and corruption. Management may involve screening, selection, monitoring, and engagement with suppliers on their environmental and social impacts. The category does not address the impacts of external factors – such as climate change and other environmental and social factors – on suppliers’ operations and/or on the availability and pricing of key resources, which is covered in a separate category. - Materials Sourcing & Efficiency
- Physical Impacts of Climate Change
-
-
Leadership and Governance
-
Business Ethics
The category addresses the company’s approach to managing risks and opportunities surrounding ethical conduct of business, including fraud, corruption, bribery and facilitation payments, fiduciary responsibilities, and other behaviour that may have an ethical component. This includes sensitivity to business norms and standards as they shift over time, jurisdiction, and culture. It addresses the company’s ability to provide services that satisfy the highest professional and ethical standards of the industry, which means to avoid conflicts of interest, misrepresentation, bias, and negligence through training employees adequately and implementing policies and procedures to ensure employees provide services free from bias and error. - Competitive Behaviour
- Management of the Legal & Regulatory Environment
- Critical Incident Risk Management
- Systemic Risk Management
-
Disclosure Topics
What is the relationship between General Issue Category and Disclosure Topics?
The General Issue Category is an industry-agnostic version of the Disclosure Topics that appear in each SASB Standard. Disclosure topics represent the industry-specific impacts of General Issue Categories. The industry-specific Disclosure Topics ensure each SASB Standard is tailored to the industry, while the General Issue Categories enable comparability across industries. For example, Health & Nutrition is a disclosure topic in the Non-Alcoholic Beverages industry, representing an industry-specific measure of the general issue of Customer Welfare. The issue of Customer Welfare, however, manifests as the Counterfeit Drugs disclosure topic in the Biotechnology & Pharmaceuticals industry.-
Access Standard
-
GHG Emissions
The category addresses direct (Scope 1) greenhouse gas (GHG) emissions that a company generates through its operations. This includes GHG emissions from stationary (e.g., factories, power plants) and mobile sources (e.g., trucks, delivery vehicles, planes), whether a result of combustion of fuel or non-combusted direct releases during activities such as natural resource extraction, power generation, land use, or biogenic processes. The category further includes management of regulatory risks, environmental compliance, and reputational risks and opportunities, as they related to direct GHG emissions. The seven GHGs covered under the Kyoto Protocol are included within the category—carbon dioxide (CO2), methane (CH4), nitrous oxide (N2O), hydrofluorocarbons (HFCs), perfluorocarbons (PFCs), sulfur hexafluoride (SF6), and nitrogen trifluoride (NF3).None -
Access & Affordability
The category addresses a company’s ability to ensure broad access to its products and services, specifically in the context of underserved markets and/or population groups. It includes the management of issues related to universal needs, such as the accessibility and affordability of health care, financial services, utilities, education, and telecommunications.-
Affordability & Pricing
Health care cost containment and health care access regulatory initiatives may place downward pricing pressures on the Medical Equipment & Supplies industry. This pressure may be increased further by consolidation among health care providers and the role of government-sponsored insurance programmes. Entities that ensure fair pricing may limit the negative effects of cost containment as well as benefitting from the potential revenue opportunities associated with expanded access. Entities that successfully balance the risks and opportunities associated with cost containment and improved access to health care may increase their market share among segments of the population that might ordinarily be less likely to seek health care.
-
-
Product Quality & Safety
The category addresses issues involving unintended characteristics of products sold or services provided that may create health or safety risks to end-users. It addresses a company’s ability to offer manufactured products and/or services that meet customer expectations with respect to their health and safety characteristics. It includes, but is not limited to, issues involving liability, management of recalls and market withdrawals, product testing, and chemicals/content/ingredient management in products.-
Product Safety
Information on product safety and side effects may be discovered after controlled clinical trials and approval. In such cases, entities are exposed to the financial implications of recalls and other adverse events, such as unfavourable media coverage, fines or investigations. Issues related to product safety, such as equipment failures, manufacturing defects, design flaws or inadequate disclosure of product-related risks, may result in significant product liability claims. Entities that limit the incidence of recalls, safety concerns and enforcement actions for manufacturing concerns may better protect shareholder value.
-
-
Customer Welfare
The category addresses customer welfare concerns over issues including, but not limited to, health and nutrition of foods and beverages, antibiotic use in animal production, and management of controlled substances. The category addresses the company’s ability to provide consumers with manufactured products and services that are aligned with societal expectations. It does not include issues directly related to quality and safety malfunctions of manufactured products and services, but instead addresses qualities inherent to the design and delivery of products and services where customer welfare may be in question. The scope of the category also captures companies’ ability to prevent counterfeit products.None -
Selling Practices & Product Labeling
The category addresses social issues that may arise from a failure to manage the transparency, accuracy, and comprehensibility of marketing statements, advertising, and labeling of products and services. It includes, but is not limited to, advertising standards and regulations, ethical and responsible marketing practices, misleading or deceptive labeling, as well as discriminatory or predatory selling and lending practices. This may include deceptive or aggressive selling practices in which incentive structures for employees could encourage the sale of products or services that are not in the best interest of customers or clients.-
Ethical Marketing
Entities in the Medical Equipment & Supplies industry face legal and regulatory challenges associated with product marketing. Direct-to-consumer advertisements for medical devices and outreach to physicians provide opportunities for entities to increase their market share. However, challenges arise from the potential for marketing off-label uses, which may result in significant fines and settlements. Corporate disclosure of legal and regulatory fines and the codes of ethics that govern marketing activities may allow investors to develop a better understanding of performance in this area.
-
-
Product Design & Lifecycle Management
The category addresses incorporation of environmental, social, and governance (ESG) considerations in characteristics of products and services provided or sold by the company. It includes, but is not limited to, managing the lifecycle impacts of products and services, such as those related to packaging, distribution, use-phase resource intensity, and other environmental and social externalities that may occur during their use-phase or at the end of life. The category captures a company’s ability to address customer and societal demand for more sustainable products and services as well as to meet evolving environmental and social regulation. It does not address direct environmental or social impacts of the company’s operations nor does it address health and safety risks to consumers from product use, which are covered in other categories.-
Product Design & Lifecycle Management
Medical equipment and supplies entities face increasing challenges associated with the human and environmental impact of the industry’s products. Entities may face consumer and regulatory pressure to limit the use of material inputs associated with health concerns, while also addressing issues such as the energy efficiency and end-of-life disposal of specific products. Entities that address these concerns while engaging in efforts to enhance product take-back may satisfy consumer demand and reduce future liabilities better.
-
-
Supply Chain Management
The category addresses management of environmental, social, and governance (ESG) risks within a company’s supply chain. It addresses issues associated with environmental and social externalities created by suppliers through their operational activities. Such issues include, but are not limited to, environmental responsibility, human rights, labour practices, and ethics and corruption. Management may involve screening, selection, monitoring, and engagement with suppliers on their environmental and social impacts. The category does not address the impacts of external factors – such as climate change and other environmental and social factors – on suppliers’ operations and/or on the availability and pricing of key resources, which is covered in a separate category.-
Supply Chain Management
Supply chain quality is essential to protecting consumer health and corporate value. Entities that fail to ensure quality and traceability throughout their supply chains may be susceptible to fines, lost revenue and reputational damage. Additionally, entities may need to manage the use of material inputs that are considered scarce. Disclosure of supply chain audit programmes, strategies to ensure traceability and management of critical materials may better inform investors how entities in this industry are protecting shareholder value.
-
-
Business Ethics
The category addresses the company’s approach to managing risks and opportunities surrounding ethical conduct of business, including fraud, corruption, bribery and facilitation payments, fiduciary responsibilities, and other behaviour that may have an ethical component. This includes sensitivity to business norms and standards as they shift over time, jurisdiction, and culture. It addresses the company’s ability to provide services that satisfy the highest professional and ethical standards of the industry, which means to avoid conflicts of interest, misrepresentation, bias, and negligence through training employees adequately and implementing policies and procedures to ensure employees provide services free from bias and error.-
Business Ethics
Entities in the Medical Equipment & Supplies industry are subject to various international, national and local laws pertaining to health care fraud and abuse. An entity’s ability to ensure compliance throughout its global and domestic operational footprint may have notable effects on enterprise viability and reputation. Corporate disclosure of legal and regulatory fines and the codes of ethics that govern interactions with health professionals may better allow investors to monitor performance in this area.
-
-
-
Access Standard
-
GHG Emissions
The category addresses direct (Scope 1) greenhouse gas (GHG) emissions that a company generates through its operations. This includes GHG emissions from stationary (e.g., factories, power plants) and mobile sources (e.g., trucks, delivery vehicles, planes), whether a result of combustion of fuel or non-combusted direct releases during activities such as natural resource extraction, power generation, land use, or biogenic processes. The category further includes management of regulatory risks, environmental compliance, and reputational risks and opportunities, as they related to direct GHG emissions. The seven GHGs covered under the Kyoto Protocol are included within the category—carbon dioxide (CO2), methane (CH4), nitrous oxide (N2O), hydrofluorocarbons (HFCs), perfluorocarbons (PFCs), sulfur hexafluoride (SF6), and nitrogen trifluoride (NF3).-
Fleet Fuel Management
The distribution of health care products and supplies requires significant transportation networks. Concern over climate change and dwindling natural resources may affect fuel pricing, and it may expose health care distributors to cost fluctuations. Entities that improve transportation efficiencies may be better positioned to create value over the long-term.
-
-
Access & Affordability
The category addresses a company’s ability to ensure broad access to its products and services, specifically in the context of underserved markets and/or population groups. It includes the management of issues related to universal needs, such as the accessibility and affordability of health care, financial services, utilities, education, and telecommunications.None -
Product Quality & Safety
The category addresses issues involving unintended characteristics of products sold or services provided that may create health or safety risks to end-users. It addresses a company’s ability to offer manufactured products and/or services that meet customer expectations with respect to their health and safety characteristics. It includes, but is not limited to, issues involving liability, management of recalls and market withdrawals, product testing, and chemicals/content/ingredient management in products.-
Product Safety
Health Care Distributors are integral to the delivery of consumer health care products. The industry has a shared responsibility with manufacturers to ensure product safety and answer concerns related to toxicity. Further, Health Care Distributors face additional risks related to controlled substances and mislabelled products. Entities that improve safety or effectively manage other product concerns may better protect shareholder value.
-
-
Customer Welfare
The category addresses customer welfare concerns over issues including, but not limited to, health and nutrition of foods and beverages, antibiotic use in animal production, and management of controlled substances. The category addresses the company’s ability to provide consumers with manufactured products and services that are aligned with societal expectations. It does not include issues directly related to quality and safety malfunctions of manufactured products and services, but instead addresses qualities inherent to the design and delivery of products and services where customer welfare may be in question. The scope of the category also captures companies’ ability to prevent counterfeit products.-
Counterfeit Drugs
The World Health Organization (WHO) estimates that counterfeit drugs represent more than 10% of the pharmaceutical supply chain in low- and middle-income countries. The issue of counterfeit or substandard medication also presents a significant risk in developed economies. Health Care Distributors may face added costs as applicable jurisdictional legal or regulatory authorities implement drug supply chain regulations to prevent counterfeit or mislabelled drugs from entering the pharmaceutical distribution system.
-
-
Selling Practices & Product Labeling
The category addresses social issues that may arise from a failure to manage the transparency, accuracy, and comprehensibility of marketing statements, advertising, and labeling of products and services. It includes, but is not limited to, advertising standards and regulations, ethical and responsible marketing practices, misleading or deceptive labeling, as well as discriminatory or predatory selling and lending practices. This may include deceptive or aggressive selling practices in which incentive structures for employees could encourage the sale of products or services that are not in the best interest of customers or clients.None -
Product Design & Lifecycle Management
The category addresses incorporation of environmental, social, and governance (ESG) considerations in characteristics of products and services provided or sold by the company. It includes, but is not limited to, managing the lifecycle impacts of products and services, such as those related to packaging, distribution, use-phase resource intensity, and other environmental and social externalities that may occur during their use-phase or at the end of life. The category captures a company’s ability to address customer and societal demand for more sustainable products and services as well as to meet evolving environmental and social regulation. It does not address direct environmental or social impacts of the company’s operations nor does it address health and safety risks to consumers from product use, which are covered in other categories.-
Product Lifecycle Management
Health Care Distributors have a responsibility to reduce the environmental impact of the products that they distribute. Specific opportunities to address these impacts exist in product packaging and take-back programmes. Entities that manage these concerns properly may meet customer demand and reduce associated costs more effectively.
-
-
Supply Chain Management
The category addresses management of environmental, social, and governance (ESG) risks within a company’s supply chain. It addresses issues associated with environmental and social externalities created by suppliers through their operational activities. Such issues include, but are not limited to, environmental responsibility, human rights, labour practices, and ethics and corruption. Management may involve screening, selection, monitoring, and engagement with suppliers on their environmental and social impacts. The category does not address the impacts of external factors – such as climate change and other environmental and social factors – on suppliers’ operations and/or on the availability and pricing of key resources, which is covered in a separate category.None -
Business Ethics
The category addresses the company’s approach to managing risks and opportunities surrounding ethical conduct of business, including fraud, corruption, bribery and facilitation payments, fiduciary responsibilities, and other behaviour that may have an ethical component. This includes sensitivity to business norms and standards as they shift over time, jurisdiction, and culture. It addresses the company’s ability to provide services that satisfy the highest professional and ethical standards of the industry, which means to avoid conflicts of interest, misrepresentation, bias, and negligence through training employees adequately and implementing policies and procedures to ensure employees provide services free from bias and error.-
Business Ethics
Health Care Distributors are subject to various jurisdictional laws and regulations regarding false marketing claims, bribery, corruption and other unethical business practices. Entities that ensure compliance with relevant regulations may avoid litigation, which could result in costly fines or settlements.
-
-
General Issue Category
Remove
Medical Equipment & Supplies
Access Standard
Remove
Health Care Distributors
Access Standard
GHG Emissions
-
Fleet Fuel Management
The distribution of health care products and supplies requires significant transportation networks. Concern over climate change and dwindling natural resources may affect fuel pricing, and it may expose health care distributors to cost fluctuations. Entities that improve transportation efficiencies may be better positioned to create value over the long-term.
Access & Affordability
-
Affordability & Pricing
Health care cost containment and health care access regulatory initiatives may place downward pricing pressures on the Medical Equipment & Supplies industry. This pressure may be increased further by consolidation among health care providers and the role of government-sponsored insurance programmes. Entities that ensure fair pricing may limit the negative effects of cost containment as well as benefitting from the potential revenue opportunities associated with expanded access. Entities that successfully balance the risks and opportunities associated with cost containment and improved access to health care may increase their market share among segments of the population that might ordinarily be less likely to seek health care.
Product Quality & Safety
-
Product Safety
Information on product safety and side effects may be discovered after controlled clinical trials and approval. In such cases, entities are exposed to the financial implications of recalls and other adverse events, such as unfavourable media coverage, fines or investigations. Issues related to product safety, such as equipment failures, manufacturing defects, design flaws or inadequate disclosure of product-related risks, may result in significant product liability claims. Entities that limit the incidence of recalls, safety concerns and enforcement actions for manufacturing concerns may better protect shareholder value.
-
Product Safety
Health Care Distributors are integral to the delivery of consumer health care products. The industry has a shared responsibility with manufacturers to ensure product safety and answer concerns related to toxicity. Further, Health Care Distributors face additional risks related to controlled substances and mislabelled products. Entities that improve safety or effectively manage other product concerns may better protect shareholder value.
Customer Welfare
-
Counterfeit Drugs
The World Health Organization (WHO) estimates that counterfeit drugs represent more than 10% of the pharmaceutical supply chain in low- and middle-income countries. The issue of counterfeit or substandard medication also presents a significant risk in developed economies. Health Care Distributors may face added costs as applicable jurisdictional legal or regulatory authorities implement drug supply chain regulations to prevent counterfeit or mislabelled drugs from entering the pharmaceutical distribution system.
Selling Practices & Product Labeling
-
Ethical Marketing
Entities in the Medical Equipment & Supplies industry face legal and regulatory challenges associated with product marketing. Direct-to-consumer advertisements for medical devices and outreach to physicians provide opportunities for entities to increase their market share. However, challenges arise from the potential for marketing off-label uses, which may result in significant fines and settlements. Corporate disclosure of legal and regulatory fines and the codes of ethics that govern marketing activities may allow investors to develop a better understanding of performance in this area.
Product Design & Lifecycle Management
-
Product Design & Lifecycle Management
Medical equipment and supplies entities face increasing challenges associated with the human and environmental impact of the industry’s products. Entities may face consumer and regulatory pressure to limit the use of material inputs associated with health concerns, while also addressing issues such as the energy efficiency and end-of-life disposal of specific products. Entities that address these concerns while engaging in efforts to enhance product take-back may satisfy consumer demand and reduce future liabilities better.
-
Product Lifecycle Management
Health Care Distributors have a responsibility to reduce the environmental impact of the products that they distribute. Specific opportunities to address these impacts exist in product packaging and take-back programmes. Entities that manage these concerns properly may meet customer demand and reduce associated costs more effectively.
Supply Chain Management
-
Supply Chain Management
Supply chain quality is essential to protecting consumer health and corporate value. Entities that fail to ensure quality and traceability throughout their supply chains may be susceptible to fines, lost revenue and reputational damage. Additionally, entities may need to manage the use of material inputs that are considered scarce. Disclosure of supply chain audit programmes, strategies to ensure traceability and management of critical materials may better inform investors how entities in this industry are protecting shareholder value.
Business Ethics
-
Business Ethics
Entities in the Medical Equipment & Supplies industry are subject to various international, national and local laws pertaining to health care fraud and abuse. An entity’s ability to ensure compliance throughout its global and domestic operational footprint may have notable effects on enterprise viability and reputation. Corporate disclosure of legal and regulatory fines and the codes of ethics that govern interactions with health professionals may better allow investors to monitor performance in this area.
-
Business Ethics
Health Care Distributors are subject to various jurisdictional laws and regulations regarding false marketing claims, bribery, corruption and other unethical business practices. Entities that ensure compliance with relevant regulations may avoid litigation, which could result in costly fines or settlements.